Monopar Therapeutics (MNPR) Current Assets (2016 - 2026)
Monopar Therapeutics (MNPR) posted Current Assets of $140.5 million for Q4 2025, down 2.52% sequentially from $144.1 million in Q3 2025, and up 132.97% YoY from $60.3 million in Q4 2024.
Monopar Therapeutics (MNPR) Current Assets (2016 - 2026) Analysis & Trends
Monopar Therapeutics has reported Current Assets for 10 years, with the latest figure at $140.5 million in Q4 2025.
- Quarterly Current Assets rose 132.97% year-over-year to $140.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $140.5 million (up 132.97% YoY) and the FY2025 annual result came in at $140.5 million, up 132.97% from the prior year.
- Current Assets eased to $140.5 million in Q4 2025 per MNPR's latest filing, from $144.1 million in the prior quarter.
- Over five years, Current Assets peaked at $144.1 million in Q3 2025 and troughed at $6.1 million in Q3 2024.
- A 5-year average of $33.5 million and a median of $17.3 million in 2022 frame the typical range for Current Assets.
- The sharpest annual moves came in 2023 and 2025: Current Assets plunged 44.31% in 2023, then soared 2273.95% in 2025.
- Over 5 years, Current Assets stood at $20.5 million in 2021, then tumbled by 35.84% to $13.2 million in 2022, then slumped by 44.31% to $7.3 million in 2023, then surged by 722.24% to $60.3 million in 2024, then soared by 132.97% to $140.5 million in 2025.
- According to Business Quant data, Current Assets over the past three periods registered $140.5 million, $144.1 million, and $53.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Monopar Therapeutics | 965.64 Mn | 912.88 Mn | - | 134.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 134.76 Mn |
| Dec 31, 2025 | 140.46 Mn |
| Sep 30, 2025 | 144.09 Mn |
| Jun 30, 2025 | 53.75 Mn |
| Mar 31, 2025 | 55.08 Mn |
| Dec 31, 2024 | 60.29 Mn |
| Sep 30, 2024 | 6.07 Mn |
| Jun 30, 2024 | 7.18 Mn |
| Mar 31, 2024 | 8.91 Mn |
| Dec 31, 2023 | 7.33 Mn |
| Sep 30, 2023 | 8.57 Mn |
| Jun 30, 2023 | 10.30 Mn |
| Mar 31, 2023 | 11.78 Mn |
| Dec 31, 2022 | 13.17 Mn |
| Sep 30, 2022 | 14.37 Mn |
| Jun 30, 2022 | 16.65 Mn |
| Mar 31, 2022 | 18.01 Mn |
| Dec 31, 2021 | 20.52 Mn |
| Sep 30, 2021 | 22.45 Mn |
| Jun 30, 2021 | 24.39 Mn |